Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioMarin acquires Zacharon Pharmaceuticals
February 2013
SHARING OPTIONS:

SAN DIEGO—BioMarin Pharmaceuticals Inc. has announced the acquisition of Zacharon Pharmaceuticals, a privately held company founded in 2004. The acquisition is priced at $10 million up front, with the potential for additional payments if clinical, regulatory and commercial milestones are met. Zacharon targets multiple forms of lysosomal storage disease and rare forms of cancer through small-molecule drugs that target glycans, with compounds in its pipeline for conditions such as Tay Sachs, metachromatic leukodystrophy and acute spinal cord injury.  
 
"The acquisition of Zacharon will further expand our glycobiology expertise and will support our lysosomal storage disease drug development efforts," said BioMarin CEO Jean-Jacques Bienaimé in a statement. "We are committed to investing in our advancing pipeline, which has evolved through a combination of internal development and targeted acquisitions, such as this."  
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.